Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Clinical neurodiagnostics

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.

Niklas Mattsson; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow; Alzheimer’s Disease Neuroimaging Initiative

Originally published in JAMA neurology · 2017-05-01

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Importance Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. Objective To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration. Design, setting, and participants In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. The study dates were September 7, 2005, to February 13, 2012. The plasma NFL analysis was performed in September 2016. Main outcomes and measures Associations were tested between plasma NFL and diagnosis, Aβ pathologic features, CSF biomarkers of neuronal injury, cognition, brain structure, and metabolism.

Results

Table 1 lists demographics for the study population. In the whole cohort, plasma NFL correlated with age (Spearman ρ = 0.35, P < .001) but not with sex (median, 36.2 ng/L for men vs 37.4 ng/L for women; P = .98), educational level (ρ = −0.03, P = .52), or APOE ɛ4 genotype (37.7 ng/L in carriers vs 35.6 ng/L in noncarriers, P = .19).

Discussion

We present the first large study, to our knowledge, on plasma NFL in AD dementia. The main findings were that plasma NFL (1) correlated with CSF NFL independent of diagnosis, (2) was increased in the AD dementia group and in Aβ-positive patients with MCI, (3) had diagnostic accuracy for AD dementia in the same range as established CSF biomarkers, and (4) was associated with cognitive deficits and neuroimaging hallmarks of AD at baseline and during follow-up.

Conclusions

We found that plasma NFL concentration is increased in AD, even in prodromal disease, and that it correlates with important disease hallmarks, measured by cognitive tests, neuroimaging, and CSF biomarkers. The fact that plasma NFL concentration is also elevated in other neurological diseases and that NFL may be released from neurons in Aβ-dependent and Aβ-independent pathologic conditions argues against the use of plasma NFL for differential diagnosis of AD vs other dementias.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?